We Offer Worldwide Shipping
Login Wishlist

Cholesterol

$43

  • Brand : BIOFRON

  • Catalogue Number : BF-C2014

  • Specification : 98%

  • CAS number : 57-88-5

  • Formula : C27H46O

  • Molecular Weight : 386.66

  • Volume : 20mg

In stock

Quantity
Checkout Bulk Order?

Catalogue Number

BF-C2014

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

386.66

Appearance

Powder

Botanical Source

Bufo gargarizans

Structure Type

Others

Category

SMILES

CC(C)CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C

Synonyms

IUPAC Name

Density

1.0±0.1 g/cm3

Solubility

Ethanol : 25 mg/mL (64.66 mM; Need ultrasonic)
DMSO : 0.79 mg/mL (2.04 mM; Need warming)

Flash Point

209.3±12.4 °C

Boiling Point

480.6±14.0 °C at 760 mmHg

Melting Point

148-150 °C

InChl

InChI=1S/C27H46O/c1-18(2)7-6-8-19(3)23-11-12-24-22-10-9-20-17-21(28)13-15-26(20,4)25(22)14-16-27(23,24)5/h9,18-19,21-25,28H,6-8,10-17H2,1-5H3/t19-,21+,22+,23-,24+,25+,26+,27-/m1/s1

InChl Key

HVYWMOMLDIMFJA-DPAQBDIFSA-N

WGK Germany

RID/ADR

HS Code Reference

2906130000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:57-88-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

PMID

32578723

Abstract

Purpose: To collect data capable of pointing out the effects of the ultracavitation treatment on the liver of rabbits after adipose tissue application, by means of histological analyses of the liver and hematological and biochemical exams.

Methods: This is an experimental study with 12 albino rabbits as sample, which were divided into 3 groups and submitted to a hypercaloric diet for one month. Subsequently, subjects underwent UCV treatment: 3 minutes, 30 W, continuous mode at 100%, every 2 ERAS = 441.02 J/cm2, intensity of 10w/cm2. They were then euthanized and underwent biopsy after 24 hours.

Results: After 48 hours from the ultracavitation treatment, the animals’ livers presented greater amount of fat infiltration if compared to the amount presented 96 hours after the treatment. However, laboratory tests showed no alterations. Values were maintained within normal parameters of cholesterol, triglycerides, liver enzymes, hemoglobin and hematocrit levels.

Conclusions: This study has identified that infiltrates may appear on livers after the treatment, despite high hematological and biochemical tests results. The fat infiltrates reduction 96 h after treatment suggests lower risks to animal health, if the period between applications is respected.

Title

Hepathic, biochemical, hematological, and histological effects of the ultracavitation in rabbits livers

Author

Patricia Froes Meyer 1, Janiele Ferreira da Silva Sousa 2, Rejane Vilar da Rocha 2, Jose Queiroz Filho 3, Oscar Ariel Ronzio 4, Rodrigo Marcel Valentim da Silva 5, Ana Camila de Medeiros Manso 6, Afra Rafaelli Magalhães de Almeida 6, Camila Procopio Andrada 7

Publish date

2020 Jun 19

PMID

32501731

Abstract

The pandemic of coronavirus disease (COVID-19) has become a global threat to public health. Functional impairments in multiple organs have been reported in COVID-19, including lungs, heart, kidney, liver, brain, and vascular system. Patients with metabolic-associated preconditions, such as hypertension, obesity, and diabetes, are susceptible to experiencing severe symptoms. The recent emerging evidence of coagulation disorders in COVID-19 suggests that vasculopathy appears to be an independent risk factor promoting disease severity and mortality of affected patients. We recently found that the decreased levels of low-density lipoprotein cholesterols (LDL-c) correlate with disease severity in COVID-19 patients, indicating pathological interactions between dyslipidemia and vasculopothy in patients with COVID-19. However, this clinical manifestation has been unintentionally underestimated by physicians and scientific communities. As metabolic-associated morbidities are generally accompanied with endothelial cell (EC) dysfunctions, these pre-existing conditions may make ECs more vulnerable to SARS-CoV-2 attack. In this mini-review, we summarize the metabolic and vascular manifestations of COVID-19 with an emphasis on the association between changes in LDL-c levels and the development of severe symptoms as well as the pathophysiologic mechanisms underlying the synergistic effect of LDL-c and SARS-CoV-2 on EC injuries and vasculopathy.

KEYWORDS

COVID-19; LDL; SARS-CoV-2; endothelial cells; hypertension; obesity; thrombosis; vasculopathy.

Title

Cholesterol: A new game player accelerating vasculopathy caused by SARS-CoV-2?

Author

Xiaoling Cao 1, Rong Yin 1, Helmut Albrecht 2 3, Daping Fan 1 4, Wenbin Tan 1 4

Publish date

2020 Jul 1;

PMID

32485329

Abstract

Intensive lipid management is critical to reduce cardiovascular (CV) risk for patients with diabetes mellitus (DM).

Methods: We performed an observational study of 7628 patients with (n = 2943) and without DM (n = 4685), enrolled in the Provider Assessment of Lipid Management (PALM) registry and treated at 140 outpatient clinics across the United States in 2015. Patient self-estimated CV risk, patient-perceived statin benefit and risk, observed statin therapy use and dosing were assessed.

Results: Patients with DM were more likely to believe that their CV risk was elevated compared with patients without DM (39.1% vs 29.3%, P < .001). Patients with DM were more likely to receive a statin (74.2% vs 63.5%, P < .001) but less likely to be treated with guideline-recommended statin intensity (36.5% vs 46.9%, P < .001), driven by the low proportion (16.5%) of high risk (ASCVD risk ≥7.5%) primary prevention DM patients treated with a high intensity statin. Patients with DM treated with guideline-recommended statin intensity were more likely to believe they were at high CV risk (44.9% vs 38.4%, P = .005) and that statins can reduce this risk (41.1% vs 35.6%, P = .02), compared with patients treated with lower than guideline-recommended statin intensity. Compared with patients with an elevated HgbA1c, patients with well-controlled DM were no more likely to be on a statin (77.9% vs 79.3%, P = .43).

Conclusions: In this nationwide study, the majority of patients with DM were treated with lower than guideline-recommended statin intensity. Patient education and engagement may help providers improve lipid therapy for these high-risk patients.

Title

Beliefs, risk perceptions, and lipid management among patients with and without diabetes: Results from the PALM registry

Author

Angela Lowenstern 1, Shuang Li 2, Salim S Virani 3, Ann Marie Navar 4, Zhuokai Li 2, Jennifer G Robinson 5, Veronique L Roger 6, Anne C Goldberg 7, Andrew Koren 8, Michael J Louie 9, Eric D Peterson 4, Tracy Y Wang 4

Publish date

2020 Jul


Description :

Empty ...